Athira Pharma (NASDAQ:ATHA – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.
Insider and Institutional Ownership
57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 19.8% of Athira Pharma shares are held by insiders. Comparatively, 28.8% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Athira Pharma and Dyadic International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Athira Pharma | N/A | -80.59% | -67.70% |
| Dyadic International | -347.92% | -116.14% | -76.15% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Athira Pharma | 0 | 0 | 1 | 0 | 3.00 |
| Dyadic International | 0 | 0 | 1 | 0 | 3.00 |
Athira Pharma currently has a consensus target price of $19.00, indicating a potential upside of 491.90%. Dyadic International has a consensus target price of $6.00, indicating a potential upside of 344.44%. Given Athira Pharma’s higher probable upside, analysts plainly believe Athira Pharma is more favorable than Dyadic International.
Risk and Volatility
Athira Pharma has a beta of 2.9, meaning that its stock price is 190% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
Earnings and Valuation
This table compares Athira Pharma and Dyadic International’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Athira Pharma | N/A | N/A | -$117.67 million | ($3.05) | -1.05 |
| Dyadic International | $2.90 million | 13.61 | -$6.80 million | ($0.28) | -4.82 |
Dyadic International has higher revenue and earnings than Athira Pharma. Dyadic International is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Athira Pharma beats Dyadic International on 7 of the 11 factors compared between the two stocks.
About Athira Pharma
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
